Skip to content

About Us
Pipeline
Partnership
- Licensing

Press Releases

Updates

Search

Search

Press Releases

Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory Diseases

Press Releases

Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory Diseases

© 2025 Vial. All Rights Reserved

Privacy Policy
Terms and Conditions